Innate Pharma Financial Report: Highlights of GAAP EPS and Revenue Growth

Thursday, 21 March 2024, 09:21

Innate Pharma has released its FY 2023 financial results, reporting a GAAP EPS of -€0.09 and revenue of €61.64M. The revenue marks a 6.9% year-over-year increase, showing positive growth for the company.
LivaRava Finance Meta Image
Innate Pharma Financial Report: Highlights of GAAP EPS and Revenue Growth

Innate Pharma Financial Report

Innate Pharma has announced its financial results for FY 2023, revealing insights into their performance. The company reported a GAAP EPS of -€0.09 and revenue of €61.64M, indicating a 6.9% year-over-year increase.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe